SAKAR

Sakar Healthcare Limited

Pharmaceutical contract and branded manufacturer of liquid orals and injectables

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

sakarhealthcare.com

Ask AI

Key metrics

Price as of 2026-10-16

Stock price

₹961.70

Market cap

2,141 Cr

Stock P/E

59.3

P/B

6.59

ROE (FY26)

9.4%

ROCE (FY26)

12.5%

Operating margin (FY26)

18.0%

Debt / equity (FY26)

0.17

OCF / EBITDA (FY26)

71.5%

OCF / EBITDA (3Y)

69.7%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Sakar Healthcare is an Indian drug maker that manufactures cancer (oncology) medicines, including oral tablets, injectables, oral liquids and the active ingredients (APIs) behind them, for Indian pharma companies and export markets.

Company snapshot

77thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives

✓Debt-to-equity of 0.17x — the company is largely funded by its own money, not borrowed funds.

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

Metric	Sept 2023	Dec 2023	Mar 2024	Jun 2024	Sept 2024	Dec 2024	Mar 2025	Jun 2025	Sept 2025	Dec 2025	Mar 2026	Jun 2026
Sales	34 Cr	37 Cr	43 Cr	41 Cr	43 Cr	43 Cr	50 Cr	53 Cr	58 Cr	70 Cr	71 Cr	73 Cr
Operating expenses (approx.)	25 Cr	28 Cr	32 Cr	30 Cr	31 Cr	32 Cr	35 Cr	40 Cr	46 Cr	52 Cr	45 Cr	52 Cr
EBITDA	9 Cr	9 Cr	11 Cr	11 Cr	12 Cr	12 Cr	16 Cr	13 Cr	11 Cr	19 Cr	26 Cr	21 Cr
OPM %	27.5%	24.2%	25.5%	26.0%	26.9%	27.1%	31.3%	24.1%	19.7%	26.4%	36.9%	29.1%
Other income	0.66 Cr	0.23 Cr	0.77 Cr	0.46 Cr	0.37 Cr	0.30 Cr	0.18 Cr	0.39 Cr	1 Cr	0.51 Cr	0.17 Cr	2 Cr
Interest	2 Cr	2 Cr	2 Cr	1 Cr	2 Cr	1 Cr	4 Cr	2 Cr	2 Cr	2 Cr	2 Cr	2 Cr
Depreciation	4 Cr	4 Cr	5 Cr	5 Cr	5 Cr	5 Cr	5 Cr	6 Cr	6 Cr	6 Cr	6 Cr	7 Cr
Profit before tax	4 Cr	3 Cr	5 Cr	5 Cr	5 Cr	5 Cr	6 Cr	5 Cr	5 Cr	11 Cr	18 Cr	15 Cr
Tax %	12.4%	30.9%	34.9%	48.7%	6.2%	17.2%	7.6%	13.3%	15.3%	6.4%	39.0%	29.5%
Net profit	4 Cr	2 Cr	3 Cr	2 Cr	5 Cr	5 Cr	6 Cr	5 Cr	5 Cr	10 Cr	11 Cr	10 Cr
EPS (₹)	₹1.68	₹0.98	₹1.46	₹1.10	₹2.17	₹2.08	₹2.66	₹2.11	₹2.03	₹4.59	₹4.96	₹4.62

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

Metric	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	95 Cr	128 Cr	133 Cr	153 Cr	178 Cr	252 Cr	Sign in free for the trailing twelve months
Operating expenses (approx.)	72 Cr	99 Cr	100 Cr	115 Cr	128 Cr	183 Cr	Sign in free for the trailing twelve months
EBITDA	23 Cr	29 Cr	33 Cr	38 Cr	50 Cr	69 Cr	Sign in free for the trailing twelve months
OPM %	23.9%	22.9%	24.9%	25.0%	28.0%	27.4%	Sign in free for the trailing twelve months
Other income	1 Cr	2 Cr	5 Cr	3 Cr	1 Cr	2 Cr	Sign in free for the trailing twelve months
Interest	2 Cr	3 Cr	6 Cr	8 Cr	9 Cr	8 Cr	Sign in free for the trailing twelve months
Depreciation	8 Cr	10 Cr	15 Cr	18 Cr	21 Cr	24 Cr	Sign in free for the trailing twelve months
Profit before tax	13 Cr	19 Cr	17 Cr	16 Cr	22 Cr	40 Cr	Sign in free for the trailing twelve months
Tax %	19.3%	19.8%	24.4%	26.6%	18.7%	23.3%	Sign in free for the trailing twelve months
Net profit	11 Cr	15 Cr	13 Cr	12 Cr	18 Cr	30 Cr	Sign in free for the trailing twelve months
EPS (₹)	₹6.87	₹8.73	₹6.59	₹5.64	₹7.97	₹13.70	Sign in free for the trailing twelve months
Dividend payout %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

Metric	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	16 Cr	17 Cr	19 Cr	22 Cr	22 Cr	22 Cr
Reserves	83 Cr	110 Cr	154 Cr	241 Cr	264 Cr	302 Cr
Borrowings	40 Cr	90 Cr	111 Cr	69 Cr	75 Cr	55 Cr
Other liabilities	39 Cr	51 Cr	52 Cr	57 Cr	55 Cr	101 Cr
Total liabilities	178 Cr	268 Cr	336 Cr	389 Cr	415 Cr	481 Cr
Fixed assets (net)	68 Cr	205 Cr	267 Cr	313 Cr	304 Cr	319 Cr
CWIP	49 Cr	1 Cr	6 Cr	0.32 Cr	17 Cr	4 Cr
Investments	—	7 Cr	3 Cr	0 Cr	0 Cr	50 Cr
Inventories	16 Cr	14 Cr	15 Cr	28 Cr	44 Cr	70 Cr
Trade receivables	12 Cr	14 Cr	22 Cr	21 Cr	31 Cr	0 Cr
Cash & bank	0.08 Cr	0.03 Cr	0.09 Cr	0.26 Cr	0.10 Cr	0.04 Cr
Other assets	32 Cr	26 Cr	22 Cr	27 Cr	20 Cr	38 Cr
Total assets	178 Cr	268 Cr	336 Cr	389 Cr	415 Cr	481 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

Metric	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	15 Cr	36 Cr	33 Cr	24 Cr	36 Cr	49 Cr
Cash from investing	-47 Cr	-90 Cr	-74 Cr	-52 Cr	-32 Cr	-28 Cr
Cash from financing	32 Cr	55 Cr	41 Cr	27 Cr	-3 Cr	-21 Cr
Net cash flow	-0.22 Cr	-0.05 Cr	0.06 Cr	0.37 Cr	-0.16 Cr	-0.05 Cr
Free cash flow (OCF − Capex)	-21 Cr	-62 Cr	-49 Cr	-35 Cr	3 Cr	49 Cr

Ratios

Metric	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROCE %	11.3%	10.1%	8.0%	7.1%	8.3%	12.5%
ROE %	10.9%	11.9%	7.4%	4.4%	6.1%	9.4%
Debtor days	48	40	60	50	63	0
Inventory days	110	70	76	119	166	192
Days payable	138	151	128	118	80	141
Cash conversion cycle	19	-41	8	51	149	51
OCF / EBITDA %	64.5%	121.7%	100.6%	63.8%	71.7%	71.5%
OCF / EBITDA % (3 years)	—	—	98.3%	92.7%	77.1%	69.7%
Debt / equity	0.41	0.70	0.64	0.26	0.26	0.17
Current ratio	1.01	1.07	1.03	1.21	1.40	1.28
Net debt / EBITDA	—	—	3.35	1.79	1.51	0.80